Last reviewed · How we verify
MCC-CRM
MCC-CRM is a meningococcal C conjugate vaccine that stimulates immune responses against Neisseria meningitidis serogroup C through conjugation of the polysaccharide capsule to a carrier protein.
MCC-CRM is a meningococcal C conjugate vaccine that stimulates immune responses against Neisseria meningitidis serogroup C through conjugation of the polysaccharide capsule to a carrier protein. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C.
At a glance
| Generic name | MCC-CRM |
|---|---|
| Also known as | MENJUGATE® |
| Sponsor | MCM Vaccines B.V. |
| Drug class | Conjugate vaccine |
| Target | Neisseria meningitidis serogroup C polysaccharide capsule |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains meningococcal C polysaccharide conjugated to a carrier protein (likely CRM197, a non-toxic diphtheria toxin variant), which enhances immunogenicity by promoting T-cell dependent B-cell responses. This conjugation approach improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive meningococcal disease caused by serogroup C strains.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C
Common side effects
- Injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Headache
Key clinical trials
- Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MCC-CRM CI brief — competitive landscape report
- MCC-CRM updates RSS · CI watch RSS
- MCM Vaccines B.V. portfolio CI